Search

everythinglearnresearchcommunity

for

Search:↓

8 months post hair transplant, OP experiences asymmetrical shedding despite using finasteride and starting minoxidil. The doctor suggests it might correct itself or be due to transplant trauma, recommending a wait-and-see approach.

A 19-year-old has been using a regimen of 5% topical minoxidil and 1mg oral finasteride for three months to combat early-onset balding. The user reports some progress and plans to continue the current treatment, while others suggest considering additional treatments like dutasteride for more aggressive cases.

The user started using minoxidil and finasteride for hair loss but stopped minoxidil due to scalp issues and tinnitus. They experienced testicular pain, shedding, and side effects like itchy chest and watery sperm, but noticed considerable hair regrowth except at the temples.

A 21-year-old shares their one-year progress using finasteride for hair loss, experiencing initial shedding but eventual regrowth, especially on the crown. They consider switching to dutasteride due to continued hair loss at the front temple and mid-scalp areas.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

An 18-year-old male with a family history of baldness started using 5% minoxidil and 0.01% finasteride spray for hair loss. Suggestions included getting a blood test, considering oral dutasteride, and trying oral minoxidil.

The user shared progress on hair restoration using dutasteride, oral minoxidil, and 2800 grafts, noting significant improvement in hair thickness and coverage. They discussed the importance of continuing DHT blockers like finasteride or dutasteride post-transplant to prevent further hair thinning.

A 21-year-old male discusses his starting position with hair loss. He mentions using Minoxidil, finasteride, and RU58841 as treatments.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.